Laser powerhouse Cynosure has recently received clearance from the US Food and Drug Administration (FDA) to market SculpSure as an effective method for non-invasive lipolysis of the flanks. The device is yet to be registered with the TGA.
SculpSure is a clinically proven treatment designed to reduce fat non-invasively by disrupting subcutaneous fat cells. It uses a 1060 nanometre laser, to treat an anatomical area in as little as 25 minutes.
“SculpSure represents an entirely new approach to non-invasive lipolysis, one that is safe and highly effective in reducing adipose tissue and does so in significantly less time than other current treatments,” says Cynosure Chairman and CEO Michael Davin.
“We believe that the combination of these benefits enables us to offer practitioners the lowest total cost of ownership of any non- invasive lipolysis treatment on the market today, which in turn significantly enhances their return on investment.”
The market is not a new one for Cynosure. The laser company has launched other fat-reduction devices, including SmartLipo and Cellulaze, however SculpSure is their first non- invasive lipolysis treatment.
The market for SculpSure
SculpSure is intended for individuals with a body mass index (BMI) of 30 or less. According to the World Health Organisation, in 2014 approximately 1.3 billion adults 18 years and older worldwide were classified as “overweight” – with a BMI between 25.0 and 29.9.
In Australia alone, more than a third of adults fall into the overweight category, as recorded in 2011/12 by the Australian Bureau of Statistics.
The science of SculpSure
Abstracts of clinical data from approximately 100 subjects treated with SculpSure were presented at the American Society of Laser Medicine and Surgery Annual Conference earlier this year. As well as fat reduction in the flanks, SculpSure can be used for non-invasive lipolysis of the abdomen.
